Not for use with other long-acting β 2-agonists. Do not exceed recommended dose. Prescribe a short-acting, inhaled β 2-agonist for acute symptoms; monitor for increased need. Monitor for signs ...

Developed with US respiratory specialist firm Innoviva, the drug (known as Breo Ellipta in the US ... in a single inhaler, the Ellipta. Sales of the drug are starting to pick up since its ...

The FDA has approved an expanded label for GlaxoSmithKline’s new Trelegy Ellipta inhaler, allowing it to ... provide a more convenient single daily dose for patients with advanced disease ...